Lenire has been studied in three company-sponsored clinical trials involving more than 600 people, plus two published reviews of patients treated in ordinary clinics. That is more evidence than most tinnitus interventions have. It is also evidence with real limitations, and the marketing figures you see quoted most often are the ones that flatter the device.
Here is what the studies found, what they did not test, and how to read the numbers.
The measures the trials use
Two questionnaires appear throughout. The Tinnitus Handicap Inventory scores from 0 to 100 and measures how much tinnitus interferes with your life. The Tinnitus Functional Index works similarly. A change of seven points on the THI is generally treated as the smallest difference a person would actually notice, so a “responder” in these trials usually means someone whose score improved by at least that much.
Neither questionnaire measures how loud the tinnitus is. They measure how much it bothers you. That distinction matters and we come back to it.
TENT-A1: the first large trial
Published in Science Translational Medicine in 2020, TENT-A1 enrolled 326 people across sites in Ireland and Germany and randomised them to different stimulation settings. Participants used the device for 12 weeks and were followed for another 12 months.
Among participants who used the device as directed, 86.2% reported an improvement in their THI score at 12 weeks, and 80.1% of those still showed improvement twelve months after finishing treatment.
The important qualifier is “as directed”. These figures describe treatment-compliant participants, not everyone who started. They also describe any improvement, including improvements smaller than the seven-point threshold. Tinnitus fluctuates on its own, and people who enrol in a trial tend to improve somewhat regardless of what they are given.
TENT-A2: refining the settings
TENT-A2, published in Scientific Reports in 2022, enrolled 191 people and tested four different combinations of stimulation settings, switching each participant to a second setting partway through.
The two main arms produced an average THI reduction of 18.5 points at 12 weeks, with individual arms ranging from 14.2 to 21.2 points. Among the 160 treatment-compliant participants, 95.0% showed improvement on the THI and 84.4% on the TFI. At the twelve-month follow-up, 91.0% of the 111 participants still being tracked showed sustained THI improvement.
An 18-point drop on the THI is a substantial change. It is roughly the difference between tinnitus being a constant intrusion and tinnitus being something you notice when the room is quiet.
The trial also recorded 156 treatment-related adverse events, 79 of which involved an increase in tinnitus. No serious adverse events occurred. Around a third of participants across the trial programme experienced some temporary worsening, usually settling before the end of the study. That is worth knowing before you start.
TENT-A3: the trial that tested the actual claim
TENT-A1 and TENT-A2 compared different Lenire settings against each other. Neither answered the question that matters most: does adding tongue stimulation do anything that sound alone does not?
TENT-A3, published in Nature Communications in 2024, was designed to test that. It enrolled 112 people across three European sites in a single-arm repeated-measures design. Each participant did six weeks of sound-only stimulation, then six weeks of the full bimodal treatment, acting as their own control.
Across the whole group, bimodal treatment did not significantly outperform sound alone.
In the subgroup with moderate or worse tinnitus, defined as a THI of 38 or above at the interim assessment, it did. Among those 44 participants, 58.6% responded to bimodal stimulation against 43.2% for sound alone, a statistically significant difference at p = 0.022. The pattern held on the TFI, at 45.5% against 29.6%, p = 0.010. Over the full 12 weeks the overall responder rate was 79.4%.
This is the single most useful result in the whole programme, and it is the one least often quoted. It says the tongue stimulation earns its place for people whose tinnitus is genuinely bothersome, and the case is weaker for people whose tinnitus is mild. It is also a modest effect: roughly fifteen percentage points more responders than sound therapy alone in the group it helps most.
Real-world results from ordinary clinics
Two studies have now reported on patients treated outside a trial protocol.
McMahan and Lim, writing in Communications Medicine in 2025, reviewed 220 patients fitted at a single clinic in Alaska, of whom 212 were available for analysis at twelve weeks. They reported a mean THI reduction of 27.8 points and a clinically significant response in 91.5% of patients, with a 95% confidence interval of 86.9% to 94.5%.
Kasper and colleagues, in the American Journal of Audiology in 2026, reviewed 140 patients at a New York clinic. Among those with moderate or worse tinnitus, the mean THI reduction was 23.8 points and 81.8% met the seven-point response threshold. Using a stricter eleven-point threshold, 71.2% responded.
Both studies point the same way as TENT-A3: the benefit concentrates in people who were substantially bothered to begin with. Both are retrospective chart reviews without a control group, which is a weaker design than a trial.
What the evidence does not establish
Four things are worth being clear about.
There has never been a sham-controlled trial. The trial authors argue a convincing placebo is not possible because both the sound and the tongue pulses are things you can plainly feel. Other researchers working on competing devices have managed to build sham arms, so this is a design choice rather than a physical impossibility. Without one, some portion of the improvement in every Lenire study is attributable to expectation, to the attention of a clinician, and to natural fluctuation.
The trials were funded by the manufacturer and the authors are connected to it. Hubert Lim, senior author on several of the papers, is Chief Scientific Officer at Neuromod, the company that makes Lenire. Craig Kasper, lead author of the 2026 clinical review, declared that he is a commercial provider of Lenire. These disclosures are made properly in the papers, and industry-funded research is normal in medical devices. It is still a reason to read the figures carefully rather than at face value.
Loudness has not been reported. The published outcomes measure distress and interference, not the volume of the sound. If your goal is for the ringing to be quieter rather than less intrusive, the trials do not tell you whether that happens.
Durability past twelve months is unknown. TENT-A2 followed participants for a year after treatment and most sustained their improvement. Beyond that point there is no published data, and TENT-A3 did not assess long-term outcomes at all.
How to read all of this
The fair summary is that bimodal neuromodulation produces a real, moderate improvement in how much tinnitus bothers people whose tinnitus is at least moderately troubling, that the improvement lasts at least a year in most people who get it, and that some of the effect in every published study is unmeasured placebo response because no trial has controlled for it.
That is a more cautious statement than “95% of patients improve”, which is the figure most commonly promoted. The 95% comes from treatment-compliant participants in a trial that compared Lenire settings against other Lenire settings, counting any improvement of any size. It is not wrong, and it is doing more work than it should.
If your tinnitus is mild, the evidence does not support paying several thousand dollars for this over sound therapy. If your tinnitus is genuinely interfering with your sleep, your concentration or your mood, the evidence supports it as a reasonable option, with the caveat that roughly two in five people in that group did not respond.
We would rather you understood that before booking than afterwards. If you want to know whether you fall into the group the evidence supports, read are you a candidate for Lenire, or see how Lenire compares with other tinnitus treatments.
Frequently asked questions
Does Lenire cure tinnitus?
No. No published evidence shows Lenire eliminating tinnitus. Its regulatory indication in the United States is to temporarily relieve symptoms. The trials measure reduction in how much tinnitus interferes with daily life, not removal of the sound.
What percentage of people respond to Lenire?
It depends which figure you use and which group. In the controlled TENT-A3 trial, 58.6% of participants with moderate or worse tinnitus responded to bimodal stimulation against 43.2% with sound alone. Real-world clinic reviews report response rates between 81.8% and 91.5%, with no control group.
Has Lenire been tested against a placebo?
No. No sham-controlled trial has been published. TENT-A3 compared bimodal stimulation against sound-only stimulation within the same participants, which is the closest comparison available.
Can Lenire make tinnitus worse?
Temporarily, in some people. TENT-A2 recorded 79 adverse events involving increased tinnitus, and roughly a third of trial participants experienced some temporary worsening, generally settling before the end of the study. No serious adverse events were reported.
How long do the benefits last?
In TENT-A2, 91% of participants still being followed at twelve months after treatment showed sustained improvement. There is no published data beyond twelve months.
Talk to someone who has read the papers
We offer Lenire at our Forestville and Epping clinics, and we will tell you if we think the evidence does not support it in your case. Call (02) 9315 8327 or book an assessment.
References
- Conlon B, Langguth B, Hamilton C, et al. Bimodal neuromodulation combining sound and tongue stimulation reduces tinnitus symptoms in a large randomized clinical study. Science Translational Medicine. 2020;12(564). doi:10.1126/scitranslmed.abb2830
- Conlon B, Hamilton C, Meade E, et al. Different bimodal neuromodulation settings reduce tinnitus symptoms in a large randomized trial. Scientific Reports. 2022;12:10845. doi:10.1038/s41598-022-13875-x
- Boedts M, Buechner A, Guerit F, et al. Combining sound with tongue stimulation for the treatment of tinnitus: a multi-site single-arm controlled pivotal trial. Nature Communications. 2024;15. doi:10.1038/s41467-024-50473-z
- McMahan EE, Lim HH. Retrospective chart review demonstrating effectiveness of bimodal neuromodulation for tinnitus treatment in a clinical setting. Communications Medicine. 2025. PMC12037789
- Kasper C, et al. Bimodal neuromodulation for tinnitus in a clinical practice setting: clinically significant benefit for patients with moderate or worse symptoms. American Journal of Audiology. 2026. doi:10.1044/2025_AJA-25-00090
- US Food and Drug Administration. De Novo classification order DEN210033, Lenire, 2023.
- Tinnitus UK. Lenire. Treatment information page.
Reviewed by Dr Signe Steers, Audiologist, The Audiology Place. Last updated September 2026. The Audiology Place supplies Lenire commercially. We have written this article to describe the evidence as it stands, including its limitations.
Always read the instructions for use. Follow the instructions for use. If symptoms persist, talk to your health professional.
